FK409 | CAS# 138472-01-2 | NO Donor

MedKoo Cat#: 565071 | Name: FK409

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FK409 is a cell permeable NO donor which produces vasorelaxation.

Chemical Structure

FK409

CAS#138472-01-2

Theoretical Analysis

MedKoo Cat#: 565071

Name: FK409

CAS#: 138472-01-2

Chemical Formula: C8H13N3O4

Exact Mass: 215.0906

Molecular Weight: 215.21

Elemental Analysis: C, 44.65; H, 6.09; N, 19.53; O, 29.74

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
50mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

92454-60-9

Synonym

NOR3; NOR 3; NOR-3; FK-409; FK 409; FK409

IUPAC/Chemical Name

(±)-(E)-4-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide

InChi Key

MZAGXDHQGXUDDX-AGLLBGTNSA-N

InChi Code

InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)/b6-4+,10-7+

SMILES Code

CC([N+]([O-])=O)/C(CC)=C/C(C(N)=O)=N\O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 215.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ueshima S, Nishida T, Koike M, Matsuda H, Sawa Y, Uchiyama Y. Nitric oxide-mediated injury of interstitial cells of Cajal and intestinal dysmotility under endotoxemia of mice. Biomed Res. 2014;35(4):251-62. PubMed PMID: 25152034. 2: Ruef P, Craciun E, Frommhold D, Kuss N, Fritzsching B, Pöschl J, Koch L. The NO-donor FK409 improves mechanical properties of activated neonatal PMN. Clin Hemorheol Microcirc. 2012;51(4):293-301. doi: 10.3233/CH-2012-1536. PubMed PMID: 22387484. 3: Ito Y, Okuda S, Ohkawa F, Kato S, Mitsufuji S, Yoshikawa T, Takeuchi K. Dual role of nitric oxide in gastric hypersecretion in the distended stomach: inhibition of acid secretion and stimulation of pepsinongen secretion. Life Sci. 2008 Dec 19;83(25-26):886-92. doi: 10.1016/j.lfs.2008.10.010. Epub 2008 Oct 30. PubMed PMID: 19000699. 4: Wang Y, Crisostomo PR, Wang M, Weil B, Abarbanell A, Poynter J, Manukyan MC, Meldrum DR. Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. Shock. 2008 Nov;30(5):527-31. doi: 10.1097/SHK.0b013e31816f1ec9. PubMed PMID: 18391852. 5: Guarda IF, Saad WA, de Arruda Camargo LA. Nitric oxide and angiotensin II receptors mediate the pressor effect of angiotensin II: a study in conscious and zoletil-anesthetized rats. Anesth Analg. 2007 Nov;105(5):1293-7, table of contents. PubMed PMID: 17959957. 6: Zhang GX, Nagai Y, Nakagawa T, Miyanaka H, Fujisawa Y, Nishiyama A, Izuishi K, Ohmori K, Kimura S. Involvement of endogenous nitric oxide in angiotensin II-induced activation of vascular mitogen-activated protein kinases. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2403-8. Epub 2007 Jul 6. PubMed PMID: 17616751. 7: Suganuma K, Tsukada K, Kashiba M, Tsuneshige A, Furukawa T, Kubota T, Goda N, Kitajima M, Yonetani T, Suematsu M. Erythrocytes with T-state-stabilized hemoglobin as a therapeutic tool for postischemic liver dysfunction. Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1847-55. PubMed PMID: 16987037. 8: Kurabayashi M, Takeyoshi I, Yoshinari D, Koibuchi Y, Ohki T, Matsumoto K, Morishita Y. NO donor ameliorates ischemia-reperfusion injury of the rat liver with iNOS attenuation. J Invest Surg. 2005 Jul-Aug;18(4):193-200. PubMed PMID: 16126630. 9: Yoshida K, Kita Y. Hydroxyimine NO-donors; FK409 and derivatives. Curr Top Med Chem. 2005;5(7):675-85. Review. PubMed PMID: 16101428. 10: Kurata H, Takaoka M, Kubo Y, Katayama T, Tsutsui H, Takayama J, Ohkita M, Matsumura Y. Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction. Eur J Pharmacol. 2005 Jul 11;517(3):232-9. PubMed PMID: 15975571. 11: Totsuka E, Murata A, Nishimura A, Umehara M, Nara M, Ono H, Nozaki T, Takiguchi M, Wajima N, Takahashi K, Seino K, Narumi S, Hakamada K, Sasaki M. Attenuation of canine warm ischemic small bowel injury by novel combination of nitric oxide donor, FK409, and cytokine suppressive anti-inflammatory agent FR167653. Transplant Proc. 2004 Sep;36(7):1988-90. PubMed PMID: 15518720. 12: Kalia N, Brown NJ, Hopkinson K, Stephenson TJ, Wood RF, Pockley AG. FK409 inhibits both local and remote organ damage after intestinal ischaemia. J Pathol. 2002 Aug;197(5):595-602. PubMed PMID: 12210078.